Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of expected sales growth.

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.